Form 4: Arrowhead Director Ferrari Granted 7,819 RSUs

Arrowhead Pharmaceuticals Director Mauro Ferrari received a grant of 7,819 restricted stock units, aligning his interests with future company performance.

Summary

• Mauro Ferrari, a Director at Arrowhead Pharmaceuticals, Inc. (ARWR), acquired 7,819 shares of Common Stock.
• These shares represent restricted stock units (RSUs) granted on December 16, 2025.
• The RSUs were granted at a transaction price of $0, indicating they were part of a compensation package.
• The shares will vest in one installment on the first anniversary of the grant date, subject to Mauro Ferrari's continued service to the Issuer.
• Following this transaction, Mauro Ferrari beneficially owns a total of 76,583 shares directly.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive sign of continued commitment and aligns the director's interests with long-term shareholder value, representing a standard and beneficial compensation practice.

Positives

• The grant of restricted stock units to Director Mauro Ferrari aligns his interests with the long-term performance and shareholder value of Arrowhead Pharmaceuticals, Inc.
• This transaction represents a standard practice in corporate compensation, reinforcing director commitment.

Risks

• The vesting of the 7,819 restricted stock units is contingent upon Mauro Ferrari's continued service to Arrowhead Pharmaceuticals, Inc. until the vesting date.

Future Outlook

The 7,819 restricted stock units granted to Director Mauro Ferrari are scheduled to vest in one installment on December 16, 2026, provided he remains in service to the company.

Industry Context

The grant of restricted stock units to directors is a common and widely accepted practice in publicly traded companies, particularly within the biotechnology and pharmaceutical sectors, serving as a key component of executive and director compensation to incentivize long-term commitment and align interests with shareholders.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) to directors is a standard compensation practice across public companies, including those in the biotechnology and pharmaceutical industries, such as Moderna, Pfizer, or Regeneron, which frequently utilize equity-based awards to attract and retain talent and align leadership with shareholder interests.
• The specific number of units granted would typically be benchmarked against peer companies of similar market capitalization, stage of development, and industry sector, though this filing does not provide such comparative data for a direct assessment against specific projects or results.

Related Party Transactions

• Director Mauro Ferrari received a grant of 7,819 restricted stock units from Arrowhead Pharmaceuticals, Inc. as part of his compensation, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the long-term performance and value creation for shareholders.
• Director: Mauro Ferrari receives additional equity compensation, increasing his stake and potential future wealth tied to the company's success.

Next Steps

• The restricted stock units are expected to vest on December 16, 2026, subject to the director's continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of restricted stock units to a director as part of their compensation. Such a transaction is a standard corporate governance practice to align director incentives with shareholder interests and does not, on its own, provide sufficient new information to alter an investment recommendation for Arrowhead Pharmaceuticals, Inc. Investors should consider broader company fundamentals and market conditions.

Keywords

Arrowhead Pharmaceuticals, ARWR, Mauro Ferrari, Form 4, SEC filing, restricted stock units, RSU, director compensation, insider transaction, equity grant, beneficial ownership